Chengdu Kanghua Biological Products (300841.SZ) shareholder Kangyue Qiming has completed the reduction period and has a total reduction of 586,000 shares.

05/03/2025

GMT Eight

Chengdu Kanghua Biological Products (300841.SZ) announced that the shareholder Kang Yueqiming's holding plan has expired, with a total of 586,000 shares being reduced.

The actual controller of Guangdong Transtek Medical Electronics (300562.SZ), Pan Weichao, has reduced his holdings by 3.6715 million shares.

Halozyme Therapeutics, Inc. (HALO.US) is set to engage in a patent battle with Merck & Co., Inc. (MRK.US) over the injectable version of Keytruda.

Contact: contact@gmteight.com

Chengdu Kanghua Biological Products (300841.SZ) shareholder Kangyue Qiming has completed the reduction period and has a total reduction of 586,000 shares.

RECOMMEND

US Stock Market Move | The weight loss drug Cagrisema's clinical trial results did not meet expectations. Novo Nordisk A/S Sponsored ADR Class B (NVO.US) dropped more than 5%.

Asiayang Group (01907) is planning an asset + cash transaction, and may take control of SINOHYTEC (688339.SH,02402) to expand its hydrogen industry chain layout.

Former US Treasury Secretary Mnuchin: Market reaction to Trump administration policies is excessive and unlikely to lead to economic recession.